Cite
HARVARD Citation
Gridelli, C. et al. (n.d.). 3109 nab-Paclitaxel (nab-P) plus carboplatin (C) as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC): Clinical outcomes by treatment cycle. European journal of cancer. pp. S638-S639. [Online].